Conquering Diseases

Study Of A Vaccine To Prevent Respiratory Syncytial Virus (Rsv) In Babies Aged 5 To 24 Months


Seeking babies aged 5 to 24 months old for a study of an mRNA vaccine to prevent respiratory syncytial virus (RSV).


Participants in this study will either get one of two doses of the experimental mRNA vaccine or a placebo (looks like the vaccine but contains no medicine). The vaccines will be given as an injection three times over a period of 4 months. After the third and final injection, there will be periodic follow-up visits over 2 years.

What we're hoping for

We are studying whether an mRNA vaccine is safe and effective in preventing respiratory syncytial virus (RSV) infection in babies aged 5 to 24 months.

Additional Information Identifier: NCT05743881

 Principal Investigator

Katherine  Luzuriaga, MD

UMass Chan Medical School

 Study Contact

The Clinical Research  Center



UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655